M&A Deal Summary

Abiomed Acquires ECP Entwicklungsgesellschaft mbH

On July 1, 2014, Abiomed acquired medical products company ECP Entwicklungsgesellschaft mbH for 13M USD

Acquisition Highlights
  • This is Abiomed’s 2nd transaction in the Medical Products sector.
  • This is Abiomed’s largest (disclosed) transaction.
  • This is Abiomed’s 2nd transaction in Germany.

M&A Deal Summary
Date 2014-07-01
Target ECP Entwicklungsgesellschaft mbH
Sector Medical Products
Buyer(s) Abiomed
Deal Type Add-on Acquisition
Deal Value 13M USD

Target

ECP Entwicklungsgesellschaft mbH

Berlin, Germany
ECP Entwicklungsgesellschaft mbH is a medical device company. ECP is developing a product that is a percutaneous, expandable catheter pump which increases blood circulation from the heart with an external drive shaft.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Abiomed

Danvers, Massachusetts, United States
Category Company
Founded 1981
Sector Medical Products
Employees1,725
Revenue 1.0B USD (2022)
DESCRIPTION

Abiomed is a cardiovascular device company. Abiomed develops, manufactures, and markets medical products designed to establish recovery's as the standard of care for acute patients. Abiomed was formed in 1981 and is based in Danvers, Massachusetts.

DEAL STATS #
Overall 2 of 4
Sector (Medical Products) 2 of 4
Type (Add-on Acquisition) 2 of 4
Country (Germany) 2 of 2
Year (2014) 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2005-04-27 Impella CardioSystems AG

Aachen, Germany

Impella CardioSystems AG, develops, manufactures and markets minimally invasive cardiovascular support systems for numerous indications in the fields of cardiology and coronary surgery.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2020-04-29 Breethe

Longueuil, Quebec, Canada

Breethe, Inc. is a developer of a novel extracorporeal membrane oxygenation (ECMO) system that will complement and expand Abiomed’s product portfolio to more comprehensively serve the needs of patients whose lungs can no longer provide sufficient oxygenation, including patients suffering from cardiogenic shock or respiratory failures such as due to ARDS, H1N1, SARS, or COVID-19. ECMO has also been utilized as a primary method of oxygenation and hemodynamic support for pediatric patients. Breethe was founded in 2014 and is based in Longueuil, Quebec.

Buy -
Mergr

Product

Company

Legal